Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen cut shares of Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) from a sell rating to a strong sell rating in a report released on Saturday morning,Wall Street Zen reports.

Other research analysts have also recently issued reports about the stock. Lake Street Capital began coverage on shares of Verrica Pharmaceuticals in a research note on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, October 13th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Verrica Pharmaceuticals has an average rating of “Hold” and an average target price of $12.67.

Get Our Latest Stock Report on VRCA

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $3.19 on Friday. The company’s 50-day moving average price is $4.24 and its two-hundred day moving average price is $5.51. The firm has a market cap of $54.80 million, a P/E ratio of -1.91 and a beta of 1.69. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. Verrica Pharmaceuticals has a 12 month low of $3.08 and a 12 month high of $9.82.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Fifth Third Bancorp raised its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) by 100.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 28,000 shares of the company’s stock after acquiring an additional 14,000 shares during the quarter. Fifth Third Bancorp owned approximately 0.16% of Verrica Pharmaceuticals worth $134,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.

Recommended Stories

Analyst Recommendations for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.